{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:49:13Z","timestamp":1761630553193,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.hoc.2010.05.006","type":"journal-article","created":{"date-parts":[[2010,7,25]],"date-time":"2010-07-25T05:25:34Z","timestamp":1280035534000},"page":"727-737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral Xa Inhibitors"],"prefix":"10.1016","volume":"24","author":[{"given":"Erica","family":"Romualdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2010.05.006_bib1","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","article-title":"Oral direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases","volume":"27","author":"Turpie","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.hoc.2010.05.006_bib2","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003495-200666110-00001","article-title":"Oral anticoagulants in development\u2014focus on thromboprophylaxis in patients undergoing orthopedic surgery","volume":"66","author":"Eriksson","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.hoc.2010.05.006_bib3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety pharmacodynamics and pharmacokinetics of BAY39-7959, an oral direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hoc.2010.05.006_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors development","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.hoc.2010.05.006_bib5","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety pharmacodynamics and pharmacokinetics of BAY39-7959, an oral direct factor Xa inhibitor\u2014after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.hoc.2010.05.006_bib6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.905.905","article-title":"The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban\u2014an oral direct Factor Xa inhibitor [abstract 905]","volume":"108","author":"Kubitza","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2010.05.006_bib7","article-title":"Effects of a single dose BAY39-7959\u2014an oral direct factor Xa inhibitor\u2014in subjects with extreme body weight [abstract 1872]","volume":"106","author":"Kubitza","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2010.05.006_bib8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/13543784.15.8.843","article-title":"Novel factor Xa inhibitors for the prevention and treatment of thromboembolic diseases","volume":"15","author":"Kubitza","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.hoc.2010.05.006_bib9","unstructured":"European Medicines Agency (EMEA). European public assessment report: Xarelto. Available at: http:\/\/www.emea.europa.eu. Accessed February 2010."},{"key":"10.1016\/j.hoc.2010.05.006_bib10","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","article-title":"BAY 59-7939: an oral direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose ranging study","volume":"3","author":"Turpie","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2010.05.006_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","article-title":"Oral direct Factor Xa inhibition with BAY59-7939 for the prevention of venous thromboembolism after total hip replacement","volume":"4","author":"Eriksson","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2010.05.006_bib12","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","article-title":"A\u00a0once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY59-7939), for thromboprophylaxis after total hip replacement","volume":"114","author":"Eriksson","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hoc.2010.05.006_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind randomized controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2010.05.006_bib14","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2010.05.006_bib15","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2010.05.006_bib16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2010.05.006_bib17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1378\/chest.126.3_suppl.338S","article-title":"Prevention of venous thromboembolism: the Seventh ACCP conference on antithrombotic and thrombolytic therapy","volume":"126","author":"Geerts","year":"2004","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.hoc.2010.05.006_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep venous thrombosis with the oral, direct factor Xa inhibitor rivaroxaban (BAY59-7939)- the ODIXa DVT (oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep vein thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hoc.2010.05.006_bib19","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A\u00a0dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2010.05.006_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.LBA-2.LBA-2","article-title":"Once daily oral rivaroxaban versus placebo in the long term prevention of recurrent symptomatic venous thromboembolism. The Einstein-Extension study [abstract 2]","volume":"114","author":"Buller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2010.05.006_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (Atlas ACS -TIMI 46): a randomised double blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2010.05.006_bib22","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1538-7836.2005.01374.x","article-title":"New anticoagulants","volume":"3","author":"Weits","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2010.05.006_bib23","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies","volume":"6","author":"Wong","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.hoc.2010.05.006_bib24","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","article-title":"In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.hoc.2010.05.006_bib25","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct, factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2010.05.006_bib26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for the thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"S2","key":"10.1016\/j.hoc.2010.05.006_bib27","article-title":"The ADVANCE 2 study: a randomized double blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement [abstract LB-MO-005]","volume":"7","author":"Lassen","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2010.05.006_bib28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Efficacy and safety of the oral direct facto Xa inhibitor apixaban for the symptomatic deep vein thrombosis. The Botticelli DVT dose ranging study","volume":"6","author":"Buller","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2010.05.006_bib29","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hoc.2010.05.006_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A\u00a0randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2010.05.006_bib31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1538-7836.2007.02436.x","article-title":"A\u00a0phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement","volume":"5","author":"Agnelli","year":"2007","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858810000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858810000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:54:04Z","timestamp":1760183644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858810000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0889858810000857"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2010.05.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Xa Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2010.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}